Relenopride is under clinical development by SK Life Science and currently in Phase I for Unspecified Neurologic Disorders. According to GlobalData, Phase I drugs for Unspecified Neurologic Disorders does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Relenopride LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Relenopride overview
Relenopride hydrochloride (YKP-10811, YKP-GI and SKL-IBS) is under development for the treatment of rare neurological diseases. The drug candidate is an enterokinetic small molecule. It acts by targeting 5-HT4 receptors. It was also under development for the treatment of chronic or functional constipation, constipation-predominant irritable bowel syndrome (c-IBS) in the form of the capsule.
SK Life Science overview
SK Life Science (SK Life), is a subsidiary of SK Biopharmaceuticals Co Ltd is a developer of next-generation drugs. The company’s pipeline products include SK-PSY which treats bipolar disorder; SKL13865 for attention deficit and hyperactivity disorder; SKL27969 treats advanced solid tumors; SKL20540 for schizophrenia; SKL24741 which targets epilepsy and others. Its therapeutic areas include central nervous system (CNS) disorder and cancer. The company collaborates with universities, government organizations, and pharmaceutical and biotech companies. SK Life is headquartered in Fair Lawn, New Jersey, the US.
For a complete picture of Relenopride’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
